Search
for
Sort by
Research 451–480 of 1000+
- An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
- JAK inhibition in the treatment of alopecia areata – a promising new dawn?
- JAK inhibition decreases the autoimmune burden in Down syndrome
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients
- Real-world experience quantifying access to JAK inhibitor care for alopecia areata patients: a patient-centered survey study
- JAK inhibition decreases the autoimmune burden in Down syndrome
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Switching JAK inhibitors: evaluating baricitinib’s effectiveness in alopecia areata after tofacitinib failure
- JAK-inhibitors in the therapy of comorbid diseases – atopic dermatitis and alopecia areata: literature review and experience of clinical practice
- 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias
- JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study
- A Review on the Use and Effectiveness of JAK Inhibitor in the Management of Lichen Planopilaris
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Multiomic Characterization of Treatment Response to JAK Inhibition in Patients with APECED
- Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- JAK Inhibitor Therapy in Alopecia Areata with Latent Hepatitis B Virus or Tuberculosis Infection: A Safety Assessment
- 0433 JAK inhibitor halts the progression of acute exacerbation of alopecia areata
- Short-term Efficacy of Tofacitinib, a JAK Inhibitor, in IFIH1-related Aicardi-Goutières Syndrome
- Clinical and Dermoscopic Evaluation of the Safety and Efficacy of Oral baricitinib (JAK Inhibitor) in Treatment of Localized Vitiligo Either Alone or with Topical Tacrolimus
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- 43647 Treatment of Refractory Folliculitis Decalvans with the Topical JAK Inhibitor Tofacitinib